We rank companies based on fund manager, research analyst and news sentiment
BGNE

BeiGene
BGNE

$141.3
3.31%
 

About: BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

Employees: 10,000

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

2% more funds holding

Funds holding: 192 [Q3] → 195 (+3) [Q4]

8% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 36

7% more call options, than puts

Call options by funds: $13.1M | Put options by funds: $12.3M

0.18% less ownership

Funds ownership: 3.77% [Q3] → 3.59% (-0.18%) [Q4]

4% less capital invested

Capital invested by funds: $8.45B [Q3] → $8.1B (-$347M) [Q4]

27% less funds holding in top 10

Funds holding in top 10: 11 [Q3] → 8 (-3) [Q4]

34% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 74

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$161
14%
upside
Avg. target
$221
56%
upside
High target
$345
144%
upside

6 analyst ratings

positive
67%
neutral
33%
negative
0%
B of A Securities
David Li
16%upside
$164.3
Neutral
Maintained
8 Apr 2024
Bernstein
Rebecca Liang
14%upside
$161
Market Perform
Maintained
27 Mar 2024
JP Morgan
Jessica Fye
32%upside
$186
Overweight
Maintained
19 Mar 2024
Guggenheim
Michael Schmidt
144%upside
$345
Buy
Maintained
27 Feb 2024
JP Morgan
Jessica Fye
31%upside
$185
Overweight
Assumed
6 Feb 2024

Financial journalist opinion